Can a chatbot help young people navigate cancer risk?
NCT ID NCT04323774
First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times
Summary
This study is testing a chatbot and online portal called AYA-RISE to help adolescents and young adults (ages 12-24) who have genetic conditions that raise their cancer risk. The goal is to see if the tool helps them communicate with family and doctors and make informed decisions about screening. About 115 participants will use the chatbot or receive standard genetic counseling, and researchers will measure how well it works and how acceptable it is.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- chatbot and online portal for cancer risk education
- What this could lead to
- If successful, this could provide a scalable tool to help young people with genetic cancer risks better understand and communicate about their health.
- What could go wrong
- This is an early feasibility study with only 115 participants, so results may not apply to everyone. The chatbot is not a treatment and does not directly reduce cancer risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER RISK SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Boston Children's Hospital
Boston, Massachusetts, 02115, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Emory University School of Medicine
Atlanta, Georgia, 30342, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Utah, Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States